title: Netupitant-palonosetron combination approved by FDA.
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Thompson
mesh_terms: D000932:Antiemetics / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects; D017277:Drug Approval; D004338:Drug Combinations; D004347:Drug Interactions; D004348:Drug Labeling; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D000077924:Palonosetron; D011725:Pyridines / Q000008:administration & dosage*; D011812:Quinuclidines / Q000008:administration & dosage*; D014481:United States; D014486:United States Food and Drug Administration; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*; D010879:Piperazines; D044482:Benzeneacetamides
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D004338:Drug Combinations; D007546:Isoquinolines; D000077924:Palonosetron; D011725:Pyridines; D011812:Quinuclidines; C508854:netupitant; D010879:Piperazines; D044482:Benzeneacetamides